Streetbeat News

Products Services

AAPL

CROX

GOOGL

PFE

SBUX

Redditors at r/ValueInvesting shared their top value stock picks, highlighting Apple Inc (AAPL) for its favorable P/E ratio compared to other tech giants. Alphabet Inc (GOOGL/GOOG), Crocs Inc (CROX), Starbucks Corp (SBUX), and Pfizer Inc (PFE) were also mentioned as undervalued investments based on their current P/E multiples. The discussion reflects a positive sentiment towards these companies, considering them attractive for their growth potential, brand popularity, and valuation.

Portfolio Pulse from Surbhi Jain

March 11, 2024 | 6:42 pm

AGR

Avangrid (AGR) is expanding its renewable energy portfolio by constructing its fifth wind farm, Osagrove Flats, in La Salle County, Illinois. The new 153 Megawatt (MW) wind farm underscores the company's ongoing commitment to investing in renewable energy within the state.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 6:35 pm

MRNA

Moderna shares are trading higher following the announcement of a new Phase 2/3 trial of pembrolizumab (Keytruda) by Merck in combination with Moderna's V940 for cutaneous squamous cell carcinoma. The trial's posting on clinicaltrials.gov and Jefferies' positive outlook on the program's investment and confidence have contributed to the optimism.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 6:09 pm

MRK

MRNA

Merck & Co Inc (NYSE:MRK) and Moderna Inc (NASDAQ:MRNA) are collaborating on a new clinical trial for V940, an individualized neoantigen therapy, combined with pembrolizumab for treating advanced cutaneous squamous cell carcinoma. The Phase 2 trial will evaluate the safety and efficacy of this combination compared to standard care. The trial is expected to start next month and conclude by 2029. Analysts from Jefferies and RBC Capital have expressed positive views on this development, highlighting the potential of the therapy and the growing incidence of cSCC. MRNA shares rose 8.96% to $112.26.

Portfolio Pulse from Vandana Singh

March 11, 2024 | 6:09 pm

MRNA

Moderna's shares are up due to the announcement of a new Phase 2/3 trial for pembrolizumab (Keytruda) plus Moderna's V940 in cutaneous squamous cell carcinoma, as listed on clinicaltrials.gov. Jefferies' commentary on the trial suggests increased investment and confidence in the program.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 6:07 pm

ETH-USD

On Sunday, 12,326.66 Ether (ETH) worth approximately $49.9M was burned, permanently removing it from circulation. This action follows the EIP-1159 upgrade implemented on August 5, 2021, which introduced a variable base fee for transactions that is burned. The Ethereum network is currently issuing new Ether at a 4% annual rate, expected to decrease to 0.5-1% with the Ethereum 2.0 upgrade, potentially making ETH a deflationary currency. The net annualized issuance rate for Ether was -15.33% yesterday.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 6:00 pm

AAPL

Apple is testing an AI-powered advertising product akin to Google's Performance Max, aiming to enhance its $7 billion advertising business. This move could significantly impact Apple's revenue stream and position in the digital advertising market.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 5:46 pm

JFBR

MESO

PIK

Mesoblast Limited's shares surged by 13.4% after announcing FDA support for an accelerated approval pathway for rexlemestrocel-L. Other stocks also saw significant movements, with Kidpik Corp. leading the gainers with a 238% increase following a reverse stock split announcement. On the losers' side, Jeffs' Brands Ltd dropped by 45.2%. The market movements were influenced by various factors including FDA approvals, strategic plans, financial results expectations, and investment proposals.

Portfolio Pulse from Avi Kapoor

March 11, 2024 | 5:41 pm

NVO

Novo Nordisk A/S (NYSE:NVO) is addressing patient harm caused by counterfeit versions of its diabetes drug, Ozempic, identified in 16 countries. CEO Lars Fruergaard Jorgensen emphasized the company's serious approach to the issue, collaborating with authorities worldwide. The demand for Novo's drugs, including weight loss-promoting ones, has led to a rise in counterfeit incidents. The FDA is investigating, and Novo Nordisk's Wegovy recently received FDA approval for expanded use. NVO shares dropped 1.01% to $131.72.

Portfolio Pulse from Vandana Singh

March 11, 2024 | 5:31 pm

YMM

ZTO

Full Truck Alliance (NYSE:YMM) reported a 25.3% revenue increase and tripled net income in Q4 last year, driven by strong investment income and new user growth. Despite a challenging environment, the company plans to continue its aggressive sales and marketing spending, which accelerated to 49.8% in the fourth quarter. This strategy has led to mixed investor reactions, with a 5.3% share price drop followed by a recovery. The company's P/S ratio is significantly higher than traditional logistics companies, reflecting investor confidence in its asset-light approach. However, its stock price has trended downward since its IPO. Full Truck Alliance's user growth outperformed many Chinese internet companies, with monthly active shippers increasing by 18.7%. The company's profits rose, benefiting from innovative technologies that enhance pricing and transaction efficiency. Despite competitive pressures, Full Truck Alliance intends to continue investing heavily in user acquisition and expects revenue growth to continue in the current quarter.

Portfolio Pulse from The Bamboo Works

March 11, 2024 | 5:19 pm